Saturday, July 11, 2026

Drug profile · INN

paroxetine mesylate

paroxetine mesylate (PEXEVA) is a serotonin transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — paroxetine mesylate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

paroxetine mesylate (PEXEVA) is a serotonin transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN paroxetine mesylate
Brand PEXEVA
Mechanism Serotonin transporter inhibitor
Target Sodium-dependent serotonin transporter
Route ORAL
Formulation CAPSULE

Mechanism of action

Serotonin transporter inhibitor

Primary target: Sodium-dependent serotonin transporter

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. citalopram hydrobromide Serotonin transporter inhibitor
  2. clomipramine hydrochloride Serotonin transporter inhibitor
  3. escitalopram oxalate Serotonin transporter inhibitor
  4. fluoxetine hydrochloride Serotonin transporter inhibitor
  5. fluvoxamine maleate Serotonin transporter inhibitor
  6. paroxetine hydrochloride Serotonin transporter inhibitor

Frequently asked questions

What is paroxetine mesylate?

paroxetine mesylate (PEXEVA) is a serotonin transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for paroxetine mesylate?

PEXEVA is a marketed brand name for paroxetine mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of paroxetine mesylate?

paroxetine mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.